BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23214190)

  • 21. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
    Yeh ET; Tong AT; Lenihan DJ; Yusuf SW; Swafford J; Champion C; Durand JB; Gibbs H; Zafarmand AA; Ewer MS
    Circulation; 2004 Jun; 109(25):3122-31. PubMed ID: 15226229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H
    Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiac pathology in patients after therapy for Hodgkin's lymphoma].
    Danilenko AA; Shakhtarina SV
    Vopr Onkol; 2011; 57(1):119-25. PubMed ID: 21598720
    [No Abstract]   [Full Text] [Related]  

  • 25. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chemotherapy and cardiotoxicity].
    Brestescher C; Pautier P; Farge D
    Ann Cardiol Angeiol (Paris); 1995 Oct; 44(8):443-7. PubMed ID: 8669796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
    Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
    Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
    Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
    Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of biomarkers in chemotherapy-induced cardiotoxicity.
    Cardinale D; Sandri MT
    Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer.
    Guldner L; Haddy N; Pein F; Diallo I; Shamsaldin A; Dahan M; Lebidois J; Merlet P; Villain E; Sidi D; Sakiroglu O; Hartmann O; Leftakopoulos D; de Vathaire F
    Radiother Oncol; 2006 Oct; 81(1):47-56. PubMed ID: 16989913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
    Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
    Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation-associated cardiovascular disease: manifestations and management.
    Adams MJ; Lipshultz SE; Schwartz C; Fajardo LF; Coen V; Constine LS
    Semin Radiat Oncol; 2003 Jul; 13(3):346-56. PubMed ID: 12903022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthracycline cardiotoxicity in childhood.
    Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R
    Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.
    Dillenburg RF; Nathan P; Mertens L
    Eur J Pediatr; 2013 Sep; 172(9):1149-60. PubMed ID: 23361962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiac toxicity in cancer therapy].
    Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I
    Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.